Researchers from Cleveland Clinic Detail New Studies and Findings in the Area of Myasthenia Gravis (Survival Outcomes of Medicare-Covered Elderly US Population With Myasthenia Gravis): Autoimmune Diseases and Conditions – Myasthenia Gravis

2025 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Current study results on Autoimmune Diseases and Conditions - Myasthenia Gravis have been published. According to news reporting from Cleveland, Ohio, by NewsRx journalists, research stated, “Survival outcomes have been inadequately studied among people with myasthenia gravis (MG) in the United States (US). We examined the impact of MG and comorbid conditions on longevity.”

Financial support for this research came from Argenx.

The news correspondents obtained a quote from the research from Cleveland Clinic, “We performed a longitudinal study using Medicare claims data (2006-2019). Incident MG cohort was identified based on the following criteria: age 65 years; 1 month of fee-for-service Parts A and B coverage; no health maintenance organization coverage; initial and subsequent MG claims within 2010-2011 separated by 28 days. A non-MG cohort of five times the number of the MG group was selected, matching for age, sex, region, and Medicare coverage duration. Overall and cause-specific mortality were compared between cohorts in the subsequent 8-10 Years using Kaplan-Meier plots and Cox proportional hazard models, adjusted for the Charlson Comorbidity Index (CCI). Cohorts of 6024 incident MG and 30,083 control beneficiaries were Included. The mortality rate was higher in the MG cohort compared to controls (66.8 vs. 57.1 per 1000-person-year, p< 0.0001). After adjusting for time-varying CCI, no significant difference in survival was observed between two cohorts (adjusted hazard ratio 1.09 [0.87-1.36], p = 0.47). Sixteen percent of deaths in the MG cohort were attributed to MG. Compared to the non-MG cohort, mortality rates (per 1000-person-year) specific to infections were higher among the MG cohort (2.0 vs. 1.2) while malignancies and dementia-specific mortality rates were lower (10.3 vs. 12.5 and 4.7 vs. 7.2), all p< 0.01.”

According to the news reporters, the research concluded: “Long-term mortality is increased in elderly MG patients compared to non-MG counterparts, driven by their higher comorbidity burden.”

This research has been peer-reviewed.

For more information on this research see: Survival Outcomes of Medicare-Covered Elderly US Population With Myasthenia Gravis. Muscle & Nerve, 2025. Muscle & Nerve can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

Our news journalists report that additional information may be obtained by contacting David Bruckman, Division of Quantitative Health Sciences, Center for Populations Health Research, Cleveland Clinic, Cleveland, Ohio, United States. Additional authors for this research include Yuebing Li, Jesse D. Schold, Benjamin Claytor, Nicholas Silvestri, Michael K. Hehir and Ikjae Lee.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/mus.70045. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Muscle & Nerve is: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)